Literature DB >> 22100374

Characterisation of focal liver lesions with unenhanced and contrast enhanced low MI real time ultrasound: on-site unblinded versus off-site blinded reading.

Joachim Hohmann1, Jan Skrok, Raffaella Basilico, Manfred Jennett, Anja Müller, Karl-Jürgen Wolf, Thomas Albrecht.   

Abstract

OBJECTIVE: To compare on-site and blinded off-site reading of baseline ultrasound (US) and contrast enhanced ultrasound (CEUS) for classification and characterisation of focal liver lesions.
MATERIALS AND METHODS: 99 patients (57 women and 42 men, age range 18-89 years, mean age: 59 years) with 53 malignant and 46 benign liver lesions were studied with unenhanced US followed by contrast enhanced US after injection of 2.4 ml SonoVue® (Bracco, Milano, Italy). Image interpretation was performed on-site with clinical information available by consensus of two readers and off-site by two independent blinded readers at two different centers. Comparison of pre and post contrast scans and of the different readers was performed. Reference examinations were histology, intraoperative US, MRI or CT.
RESULTS: Sensitivity for malignancy improved from 81/89/66% (on-site/off-site reader 1/2) before to 100/96/96% post contrast administration (p<0.05, except for reader 1). Specificity improved from 48/48/54% on baseline US to 89/80/76% on CEUS (p<0.05). Accuracy for specific lesion diagnosis was 62/59/50% pre and 90/77/72% post contrast (p<0.05). Classification and characterisation post contrast were mildly inferior for off-site reading. Agreement between on-site and off-site readers of unenhanced scans was fair (κ=0.29-0.39) while it was good for CEUS (κ=0.63-0.79).
CONCLUSIONS: CEUS improves classification and characterisation of focal liver lesions and interobserver agreement compared to conventional US. Classification and characterisation post contrast were mildly but statistically significantly better for on-site than for off-site reading.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22100374     DOI: 10.1016/j.ejrad.2011.10.015

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

Review 1.  Contrast-enhanced US for characterization of focal liver lesions: a comprehensive meta-analysis.

Authors:  Menglin Wu; Liang Li; Jiahui Wang; Yanyan Zhang; Qi Guo; Xue Li; Xuening Zhang
Journal:  Eur Radiol       Date:  2017-11-30       Impact factor: 5.315

2.  Contrast Enhanced Ultrasound in CT-undetermined Focal Liver Lesions.

Authors:  S W Sandrose; S Karstrup; O Gerke; S Rafaelsen
Journal:  Ultrasound Int Open       Date:  2016-11

3.  Interactive Outlining of Pancreatic Cancer Liver Metastases in Ultrasound Images.

Authors:  Jan Egger; Dieter Schmalstieg; Xiaojun Chen; Wolfram G Zoller; Alexander Hann
Journal:  Sci Rep       Date:  2017-04-18       Impact factor: 4.379

4.  The contribution of qualitative CEUS to the determination of malignancy in adnexal masses, indeterminate on conventional US - a multicenter study.

Authors:  Xinling Zhang; Yongjiang Mao; Rongqin Zheng; Zhijuan Zheng; Zeping Huang; Dongmei Huang; Jing Zhang; Qing Dai; Xiaodong Zhou; Yanling Wen
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

5.  Algorithm guided outlining of 105 pancreatic cancer liver metastases in Ultrasound.

Authors:  Alexander Hann; Lucas Bettac; Mark M Haenle; Tilmann Graeter; Andreas W Berger; Jens Dreyhaupt; Dieter Schmalstieg; Wolfram G Zoller; Jan Egger
Journal:  Sci Rep       Date:  2017-10-06       Impact factor: 4.379

6.  Prospective assessment of diagnostic efficacy and safety of SonazoidTM and SonoVue® ultrasound contrast agents in patients with focal liver lesions.

Authors:  Ke Lv; Hongyan Zhai; Yuxin Jiang; Ping Liang; Hui-Xiong Xu; Lianfang Du; Yi-Hong Chou; Xiaoyan Xie; YuKun Luo; Young Joon Lee; Jae Young Lee; Bing Hu; Baoming Luo; Yi Wang; Ying Luan; Christina Kalli; Kun Chen; Wenping Wang; Ja-Der Liang
Journal:  Abdom Radiol (NY)       Date:  2021-06-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.